Sirolimus for Autoimmune Disease of Blood Cells
Keywords
Abstract
Description
Patients with autoimmune destruction of hematopoietic cells frequently have severe and debilitating disease requiring aggressive and frequent medical management. These patients are often treated with non-specific immunosuppressive medications with limited efficacy and untoward side-effect profiles. We have been investigating the use of an immunosuppressive and anti-cancer agent, sirolimus in patients with an autoimmune cytopenias syndrome: Autoimmune Lymphoproliferative Syndrome (ALPS). ALPS is a primary immune deficiency caused by mutations in the Fas apoptotic pathway, leading to abnormal lymphocyte survival. Clinical manifestations in patients with ALPS typically include autoimmune cytopenias, lymphadenopathy, hepatosplenomegaly, and a propensity to develop secondary malignancies. Thus, far we have found excellent results albeit the total number of patients treated is small.
Sirolimus is a signal transduction inhibitor with a tolerable side effect profile. Sirolimus has two properties making it an attractive agent to treat patients with autoimmune cytopenias syndromes, including ALPS. First, sirolimus induces apoptosis in normal and abnormal white blood cells, the cell type dysregulated in patients with autoimmune disease. In addition, sirolimus increases a T cell subset called Regulatory T cells (Tregs). Tregs are a cell population designed to suppress the immune system and control autoimmunity. These combined properties make sirolimus unique as compared with other immunosuppressive agents. Ample preclinical and clinical data exists demonstrating sirolimus in effective in patients with autoimmunity. Accordingly, we hypothesize sirolimus is a safe and efficacious medication for patients with autoimmune destruction of blood cells..
We plan to confirm our hypotheses by performing a pilot series in children with autoimmune cytopenias who are either refractory to standard therapy or have significant toxicity from standard treatments. Our primary aim is to define the toxicities of administration of oral sirolimus in children with autoimmune cytopenias. Our secondary aims are to evaluate the efficacy of sirolimus in children with autoimmune cytopenias, to determine the trough levels of sirolimus when used in these patients, and to evaluate the effects of sirolimus on intracellular targets of mammalian target of rapamycin (mTOR). We intend to enroll 50 children with autoimmune cytopenias and treat for a 6 month period, however, if we find sirolimus is effective, we anticipate these children will continue to take sirolimus for a longer period of time. We anticipate the results of this work will establish sirolimus is an effective and well tolerated medication and will lead directly to a larger national phase II clinical trial.
Dates
| Last Verified: | 10/31/2019 |
| First Submitted: | 10/23/2006 |
| Estimated Enrollment Submitted: | 10/23/2006 |
| First Posted: | 10/25/2006 |
| Last Update Submitted: | 11/05/2019 |
| Last Update Posted: | 11/18/2019 |
| Date of first submitted results: | 05/31/2017 |
| Date of first submitted QC results: | 11/01/2017 |
| Date of first posted results: | 12/05/2017 |
| Actual Study Start Date: | 11/30/2006 |
| Estimated Primary Completion Date: | 01/31/2016 |
| Estimated Study Completion Date: | 01/31/2016 |
Condition or disease
Intervention/treatment
Drug: Sirolimus treatment
Phase
Arm Groups
| Arm | Intervention/treatment |
|---|---|
| Experimental: Sirolimus treatment Sirolimus treatment | Drug: Sirolimus treatment Tablet or liquid; taken once or twice daily; dosage is based on establishing a serum trough of 5-15 ng/ml by high-performance liquid chromatography (initial loading dose of 3 mg/m2 then 2.5 mg/m2 with adjustment based on serum trough) |
Eligibility Criteria
| Ages Eligible for Study | 1 Year To 1 Year |
| Sexes Eligible for Study | All |
| Accepts Healthy Volunteers | Yes |
| Criteria | Inclusion Criteria: - Age > 12 months and < 30 years at the time of study entry - Diagnosis of autoimmune cytopenias requiring treatment with medications - At least one of the following: Autoimmune Neutropenia, Autoimmune Hemolytic Anemia, and/or Autoimmune Thrombocytopenia - Must be proven autoimmune by either a documented autoantibody (positive direct anti globulin test, positive anti-neutrophil, and/or anti-platelet antibody) and/or a documented clinical response to immunosuppression - Autoimmune Cytopenias can be idiopathic (Idiopathic Thrombocytopenic Purpura (ITP), Autoimmune Hemolytic Anemia (AIHA), Autoimmune Neutropenia (AIN), or Evans syndrome) or secondary to one of following conditions: Lupus, Rheumatoid Arthritis (RA), ALPS (Autoimmune Lymphoproliferative Syndrome), or Inflammatory bowel disease (IBD) - Patients must have chronic disease diagnosed by either a documented cytopenia syndrome (Lupus, ALPS, RA, or IBD), or by having Evans syndrome defined as idiopathic destruction of multiple blood cell types, and/or by having disease >6 months - Patients must be refractory to or unable to tolerate standard front-line therapies for autoimmune cytopenias (corticosteroids and/or IVIG) - Patients may be taking second-line agents for autoimmune cytopenias (mycophenolate mofetil, cyclosporine, tacrolimus, mercaptopurine, and/or methotrexate) at time of study entry; however, attempts should be made to wean these agents. Patients may not stay on a combination of sirolimus and a calcineurin inhibitor for greater than 4 weeks - Informed consent/assent must be obtained prior to initiating treatment - Patient must be able to consume oral medication in the form of tablets or solution Exclusion Criteria: - Pregnancy or breast feeding - Uncontrolled infection - Known allergy to Sirolimus or its components - Patients with a documented malignancy on therapy or not in remission - Patients who do not meet organ function requirements listed in protocol - Patients with a documented history of severe combined immunodeficiency or human immunodeficiency virus infection (HIV) |
Outcome
Primary Outcome Measures
1. Number of Participants With Grade 3 and 4 Toxicities of Administration of Oral Sirolimus [6 months]
Secondary Outcome Measures
1. Number of Participants With Autoimmune Disease Response to Oral Sirolimus [6 months]
2. Trough Levels Produced by Administration of Oral Sirolimus [Within first 5 days of starting sirolimus]
3. Effect of Sirolimus on Intracellular Targets [6 months]
4. Number of Participants With Lymphoproliferation Response to Oral Sirolimus [6 months]
